Adverse Outcomes Associated With Short‐Acting Beta‐Agonist Overuse in Asthma: A Systematic Review and Meta‐Analysis
Allergy · 2025-06 · 80 (6) · 1629-1646
DOI: 10.1111/all.16538 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Allergy, online erschienen am 10.06.2025. Verfasst von Chia-Ling Tsao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Asthma, Adrenergic beta-Agonists, Anti-Asthmatic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
The 2019 Global Initiative for Asthma (GINA) report no longer recommended short‐acting beta‐agonists (SABA) monotherapy due to associated complications and a lack of anti‐inflammatory properties. This systematic review and meta‐analysis aimed to evaluate adverse outcomes associated with SABA overuse in patients with asthma.
Methods
PubMed, Cochrane Library, EMBASE, and Web of Science databases were searched for studies on SABA overuse (≥ 3 SABA canisters/year) in patients with asthma, from 1981 to November 2023. Randomized controlled trials (RCTs), cohort studies, and cross‐sectional studies were included. Pooled risk ratios (RRs) were calculated for dichotomous measures of all‐cause mortality and acute exacerbations using random‐effects models and Mantel‐Haenszel weighting. Subgroup analyses were conducted based on study design.
Results
Out of 626 records, 27 studies (2 RCTs, 1 prospective cohort study, 12 retrospective cohort studies, and 12 cross‐sectional studies) were included. SABA overuse (≥ 3 SABA canisters/year) was associated with significantly higher mortality (2743 of 130,629 in the overuse group versus 3534 of 300,451 in controls; RR = 2.04, 95% confidence interval, CI = 1.37–3.04; p < 0.001) and a significantly higher rate of acute exacerbations (60,320 of 165,271 in the overuse group versus 84,439 of 376,845 in controls; RR = 1.93, 95% CI = 1.24–3.03; p < 0.001). An increased risk of acute exacerbations was observed in retrospective cohort studies (RR = 1.88, 95% CI = 1.43–2.47; p < 0.001) and cross‐sectional studies (RR = 2.23, 95% CI = 1.04–4.77; p < 0.001).
Conclusions
SABA overuse was associated with increased rates of mortality and acute exacerbations in patients with asthma, supporting guidelines that advise against SABA monotherapy in asthma management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Department of Internal Medicine, Weiss Memorial Hospital, Chicago, Illinois, USA.
- Department of Internal Medicine, Maimonides Medical Center, Brooklyn, New York, USA.
- Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Kevin Sheng-Kai Ma
Zitieren
APA
Tsao, C. L., Chan, S. Y., Lee, M. H., Hsieh, T. Y. J., Phipatanakul, W., Ruran, H. B., & Ma, K. S. (2025). Adverse Outcomes Associated With Short‐Acting Beta‐Agonist Overuse in Asthma: A Systematic Review and Meta‐Analysis. Allergy, 80(6), 1629-1646. https://doi.org/10.1111/all.16538
Vancouver
Tsao CL, Chan SY, Lee MH, Hsieh TYJ, Phipatanakul W, Ruran HB, et al. Adverse Outcomes Associated With Short‐Acting Beta‐Agonist Overuse in Asthma: A Systematic Review and Meta‐Analysis. Allergy. 2025;80(6):1629-1646. doi:10.1111/all.16538
BibTeX
@article{Tsao2025,
author = {Tsao, Chia-Ling and Chan, Shu-Yen and Lee, Meng-Hsun and Hsieh, Tina Yi Jin and Phipatanakul, Wanda and Ruran, Hana B and Ma, Kevin Sheng-Kai},
title = {Adverse Outcomes Associated With Short‐Acting Beta‐Agonist Overuse in Asthma: A Systematic Review and Meta‐Analysis},
journal = {Allergy},
year = {2025},
volume = {80},
number = {6},
pages = {1629--1646},
doi = {10.1111/all.16538}
}
EUVIMED